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ells lacking vinculin are highly metastatic and motile.
The reasons for this ﬁnding have remained unclear.
Both enhanced survival and motility are critical to
metastasis. Here, we show that vinculin null (vin
 
 
 
/
 
 
 
) cells and
cells expressing a vinculin Y822F mutant have increased
survival due to up-regulated activity of extracellular signal–
regulated kinase (ERK). This increase is shown to result
from vinculin’s modulation of paxillin–FAK interactions. A
vinculin fragment (amino acids 811–1066) containing the
paxillin binding site restored apoptosis and suppressed ERK
C
 
activity in vin
 
 
 
/
 
 
 
 cells. Both vinY822F and vin
 
 
 
/
 
 
 
 cells
exhibit increased interaction between paxillin and fo-
cal adhesion kinase (FAK) and increased paxillin and
FAK phosphorylation. Transfection with paxillin Y31FY118F
dominant-negative mutant in these cells inhibits ERK activa-
tion and restores apoptosis. The enhanced motility of vin
 
 
 
/
 
 
 
and vinY822F cells is also shown to be due to a similar
mechanism. Thus, vinculin regulates survival and motility
via ERK by controlling the accessibility of paxillin for FAK
interaction.
 
Introduction
 
Adhesion complexes (i.e., focal adhesions and focal complexes)
and cell–cell contacts are specialized structures that harbor a
large number of cytoskeletal proteins and one of the highest
concentrations of signaling molecules in cells (Ruoslahti and
Obrink, 1996). These multiprotein complexes are capable of
capturing and integrating many signals from the extracellular
as well as intracellular environments (Rosales and Juliano,
1995). Such signals are indispensable for the coordinated
control of fundamental cellular processes including differen-
tiation, cell cycle control, apoptosis, and motility (Ruoslahti
and Obrink, 1996; Huang and Ingber, 2000). Coordinating
these processes is critical for the maintenance of tissue ho-
meostasis (Huang and Ingber, 2000). In fact, disruption in
the regulation of motility and survival is a major step in the
pathogenesis of cancer (Parise et al., 2000).
Disregulation in the control of multiple cellular processes
is seen in cells with altered expression and/or activation of
molecules in focal adhesions and cell–cell contacts. Such
molecules include paxillin, FAK (Rodina et al., 1999), and
vinculin (Raz and Geiger, 1982; Lifschitz-Mercer et al.,
1997). Cancer cells devoid of vinculin (Rudiger, 1998) are
highly metastatic (Raz and Geiger, 1982; Lifschitz-Mercer et
al., 1997) and motile (Coll et al., 1995; Xu et al., 1998a,b).
Transfecting vinculin back into vinculin null cells remarkably
represses their metastatic capacity (Rodriguez-Fernandez et
al., 1992) as well as their enhanced motility (Coll et al.,
1995; Xu et al., 1998b). The mechanisms through which
vinculin controls motility and represses metastatic capacity
remain unclear.
Highly metastatic cells, such as those lacking vinculin
(Rodriguez-Fernandez et al., 1992), are usually very motile
(Parise et al., 2000). Enhanced cell motility has been associ-
ated with increased survival (Frisch and Francis, 1994).
Recent evidence has shown the existence of signaling cascades
that coordinate these two processes (Cho and Klemke, 2000).
Thus, vinculin could affect signaling through multiple
proteins that mediate both survival and motility and are
found in focal adhesions and/or cell–cell contacts. These
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proteins include p130 Crk-associated substrate (Cas) and
Crk-II adaptor proteins (Nakamoto et al., 1997; Cho
and  Klemke, 2000), extracellular signal–regulated kinase
(ERK)1/2 (Klemke et al., 1997; Fincham et al., 2000), phos-
phatidylinositol-3 kinase (PI-3K; Watton and Downward,
1999; Sasaki et al., 2000), and FAK (Hauck et al., 2002).
FAK is a particularly important signaling molecule, as it
controls multiple fundamental cellular processes by regulat-
ing the assembly of different multiprotein complexes
(Tachibana et al., 1995; Schwartz, 2001). Interaction be-
tween FAK and the adaptor protein paxillin is critical for the
activation of signaling cascades involved in the control of cell
survival and motility (Turner, 2000). FAK binds to paxillin
through its COOH-terminal focal adhesion targeting (FAT)
region (Hayashi et al., 2002). This FAT region is also con-
tained within FAK-related nonkinase (FRNK), a naturally
occurring fragment of FAK (Richardson and Parsons, 1996).
Transfection with FRNK blocks the interaction of endoge-
nous FAK with paxillin at focal adhesions, decreasing sur-
vival and motility (Richardson and Parsons, 1996; Hauck et
al., 2000, 2002). Mutagenesis studies have shown that this
interaction requires the sequence of the FAT region in
FRNK (Hauck et al., 2002). Interestingly, the structure of
the FAT region resembles that of vinculin’s COOH-termi-
nal “tail domain” (Bakolitsa et al., 1999; Hayashi et al.,
2002). Furthermore, the FAT region and vinculin tail bind
to overlapping repeats of leucine-rich sequences in paxillin
named LD motifs (Turner et al., 1999; Turner, 2000; Tum-
barello et al., 2002), suggesting that vinculin too may inhibit
important FAK interactions. These observations led us to ex-
amine whether or not the highly metastatic and motile vin-
culin null cells have enhanced survival, and whether or not
enhanced survival and the enhanced motility previously re-
ported were due to disregulation of paxillin–FAK interac-
tions. In this paper, we describe a novel pathway whereby
vinculin controls cell survival and motility through regula-
tion of paxillin–FAK interactions to alter ERK1/2 activation.
 
Results
 
Vinculin null cells are resistant to apoptosis
 
To test whether or not vinculin is important in apoptosis,
we first examined apoptosis induced by serum withdrawal.
Apoptosis was compared in wild-type mouse F9 embryonal
Figure 1. Vinculin null F9 embryonal carci-
noma cells are resistant to a variety of apoptotic 
stimuli. (A) Detergent lysates from WT F9, F9 
vin
 / , and F9 vin
 /  rescue cells were analyzed 
by immunoblotting using anti–caspase-3 Ab 10 h 
after serum deprivation. The result shown is 
representative of three independent experiments. 
(B) DEVD-AMC cleavage, indicative of caspase-3 
and -7 activation, was compared for WT F9 
cells, F9 vin
 / , and F9 vin
 /  rescue cells 10 h 
after serum withdrawal. (C) Cell extracts from 
WT F9, F9 vin
 / , and F9 vin
 /  rescue cells 
were analyzed by immunoblotting using anti–
caspase-3 Ab 3 h after disruption of cell–matrix 
interaction. The result shown is a representative 
example from three independent experiments. 
(D) DEVD-AMC cleavage was compared for 
WT F9 cells, F9 vin
 / , and F9 vin
 /  rescue cells 
3 h after disruption of cell–matrix interaction. 
(E) Immunoblotting analysis of cell extracts 
from WT F9, F9 vin
 / , and F9 vin
 /  rescue 
cells treated for 2 h with 2  M camptothecin 
using anti–caspase-3 Ab. The result shown is 
representative of three independent experiments. 
(F) DEVD-AMC cleavage was compared for WT 
F9 cells, F9 vin
 / , and F9 vin
 /  rescue cells 
2 h after exposure to 2  M camptothecin. 
(G) Camptothecin-induced apoptotic cell death 
was also assessed through cellular morphologic 
changes. In B, D, F, and G, results shown are 
means   SEM from at least three independent 
experiments. DEVD-AMC cleavage is shown in 
arbitrary fluorescence intensity units. 
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carcinoma cells (WT F9), their vinculin null counterparts
(F9 vin
 
 
 
/
 
 
 
), and F9 vin
 
 
 
/
 
  
 
rescue cells (stable cell lines in
which vinculin had been reintroduced into the F9 vin
 
 
 
/
 
 
 
cells). Caspase-3 activation was assessed as an indicator of
irreversible commitment to apoptosis (Nicholson et al.,
1995). WT F9 cells exhibited caspase-3 activation reflected
by the presence of cleaved caspase-3 after 10 h of serum
withdrawal (Fig. 1 A). In contrast, F9 vin
 
 
 
/
 
 
 
 cells showed a
remarkable inhibition of caspase-3 activation, and caspase-3
activity was restored in the F9 vin
 
 
 
/
 
  
 
rescue cells (Fig. 1
A). 
 
N
 
-acetyl-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin
(DEVD-AMC) cleavage quantifies the activity of caspase-3
as well as caspase-7 (Nicholson et al., 1995; He et al., 1998).
Activation of caspase-7 is also an indicator of irreversible
commitment to apoptosis (He et al., 1998; Riedl et al.,
2001). DEVD-AMC cleavage was inhibited by 70% in F9
vin
 
 
 
/
 
  
 
cells compared with WT F9 cells after 10 h of serum
withdrawal and was fully restored to wild-type levels in the
F9 vin
 
 
 
/
 
  
 
rescue cells (Fig. 1 B).
The role of vinculin in anoikis, apoptosis induced by de-
tachment from the cellular substrate (Frisch and Francis,
1994), was also examined. Caspase-3 activation and DEVD-
AMC cleavage were remarkably inhibited in F9 vin
 
 
 
/
 
  
 
cells
compared with WT F9 cells (Fig. 1, C and D). Here too,
both caspase-3 activation and DEVD-AMC cleavage were
restored to wild-type levels in F9 vin
 
 
 
/
 
 
 
 rescue cells.
Finally, caspase-3 activity and DEVD-AMC cleavage in-
duced by 2-h incubation with camptothecin (Hertzberg et
al., 1989), a cytotoxic drug widely used in cancer therapy,
was also inhibited in F9 vin
 
 
 
/
 
  
 
cells compared with WT F9
cells (Fig. 1, E and F). The effect of camptothecin on cas-
pase-3 activity was similar in wild-type and F9 vin
 
 
 
/
 
 
 
 rescue
cells. The rate of camptothecin-induced apoptosis was also
determined using morphological criteria (blebbing and cell
fragmentation; Subauste et al., 2000). As shown in Fig. 1 G,
this rate was considerably reduced in F9 vin
 
 
 
/
 
 
 
 cells com-
pared with WT F9 or F9 vin
 
 
 
/
 
 
 
 rescue cells. We also found
that vinculin null embryonal fibroblasts are resistant to vari-
ous apoptotic stimuli (unpublished data). Together, these
findings show that vinculin regulates apoptosis induced by
multiple different stimuli.
 
Vinculin regulation of apoptosis requires its 
hinge-tail fragment
 
Vinculin has multiple binding sites for interaction with
components of cell contact sites (Rudiger, 1998). It consists
of a large amino-terminal head and a rodlike tail connected
by a flexible hinge region (840–857 aa; Rudiger, 1998). To
address which regions of vinculin are important for control
of apoptosis, cell death was examined in a F9 vin
 
 
 
/
 
 
 
 cell
clone (
 
 
 
229) stably transfected with vinculin mutants (see
Fig. 3). Results were confirmed with a different F9 vin
 
 
 
/
 
 
 
cell clone (
 
 
 
227; see Fig. 4). For this work, we used cell
clones derived from stable cell lines transfected with each
construct (Fig. 2). Except for the hinge-tail fragment, the ex-
pression of these constructs was corroborated through im-
munoblotting with an antivinculin antibody (Ab; Fig. 2 B).
The hinge-tail fragment is Flag tagged, so its expression was
confirmed using an anti-Flag M2 Ab (Fig. 2 C).
The hinge-tail fragment (811–1066 aa) was able to restore
apoptosis to wild-type levels, whereas the head fragment
(1–821 aa) could not (Fig. 3, A and B), for apoptosis induced
by serum withdrawal (Fig. 3, A and B) or anoikis (Fig. 3 C).
This finding indicated that the critical portion of the vincu-
lin molecule was within 811–1066 aa. Interestingly, the vin-
culin fragment 243–1066, in which there were deleted talin
binding sites (
 
 
 
 talin bs mutant), could not restore apoptosis
(Fig. 3, A–C). This fragment cannot localize into focal adhe-
sions (Goldmann et al., 1998) but can interact with 
 
 
 
-cate-
nin, a protein only present in cell–cell contacts (unpublished
data), suggesting that focal adhesion localization is impor-
tant for vinculin’s regulation of apoptosis.
Vinculin with a Y822F point mutation was unable to re-
store apoptosis induced by serum withdrawal or cellular de-
Figure 2. Role of various regions of vinculin in the control of 
apoptosis induction. (A) Vinculin mutants: the top line represents 
full-length vinculin. First mutant: head fragment (1–821). Second 
mutant: vinculin fragment with talin binding site deleted (243–1066). 
Third mutant: full-length vinculin containing a Y822F point mutation. 
Fourth mutant: hinge-tail fragment (811–1066). (B) Expression of 
these constructs, except for the hinge-tail fragment, was determined 
by immunoblotting with an antivinculin Ab. (C) Expression of the 
Flag M2-tagged hinge-tail fragment was determined by immuno-
blotting with an anti-Flag Ab. 
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tachment, as demonstrated both by monitoring caspase-3
cleavage (Fig. 3, A–C) and DEVD-AMC cleavage (Fig. 3
D). Vinculin Y822F is able to localize into focal adhesions
(Goldmann et al., 1998), suggesting that the mutation likely
disrupts a specific interaction with vinculin’s binding part-
ners. The aforementioned data were also reproduced using a
different F9 vin
 
 
 
/
 
 
 
 cell clone (
 
 
 
227) stably transfected with
the various vinculin mutants (Fig. 4). Together, these data
show that vinculin regulates apoptosis through its hinge-tail
region via a process occurring within focal complexes.
 
Vinculin affects apoptosis by modulating ERK1/2 activity
 
Our results showed that vinculin controls apoptosis. Because
vinculin also affects cellular motility (Coll et al., 1995), we
searched for a signaling pathway through which vinculin
might regulate both processes. ERK1/2 regulates motility
and apoptosis and localizes in focal adhesions (Klemke et al.,
1997; Fincham et al., 2000; Howe et al., 2002). Further-
more, ERK1/2 activity is elevated in cells that are highly
metastatic and resist anoikis (Howe et al., 2002). Therefore,
we assessed whether or not vinculin affected apoptosis by
regulating ERK1/2 activity, concentrating on anoikis be-
cause of its significance in cancer biology (Frisch and Francis
1994; Howe et al., 2002).
As shown in Fig. 5 A, treatment of F9 vin
 
 
 
/
 
 
 
 and F9
vinY822F with ERK antisense oligonucleotides restored
anoikis-induced caspase-3 activation. Antisense treatment
was shown to reduce ERK protein levels, scrambled antisense
oligonucleotide controls had no effect, and blotting with
anti-Erk Abs demonstrated that each cell line had similar Erk
concentrations before antisense treatment (Fig. 5, A and B).
ERK1/2 is activated upon phosphorylation of its regu-
latory threonine and tyrosine residues by MAPK kinase
(MEK; Ahn et al., 1991). The MEK inhibitor PD98059 re-
stored caspase-3 activation to wild-type levels in F9 vin
 
 
 
/
 
 
 
and F9 vin
 
 
 
/
 
 
 
Y822F cells (Fig. 5 C), and this increase was
largely eliminated by MEK inhibition (Fig. 5 D). This find-
ing indicated that anoikis resistance was mediated by activa-
tion of the MEK–ERK pathway.
We also examined ERK1/2 activity in the apoptosis-resis-
tant F9 vin
 
 
 
/
 
 
 
 and F9 vin
 
 
 
/
 
 
 
Y822F cells, and the apoptosis-
sensitive F9 vin
 
 
 
/
 
  
 
hinge-tail and WT F9 cells. Lysates from
these cells were probed with Abs specific for the active, phos-
phorylated forms of ERK1/2 at different times after cellular
detachment (Fig. 5 E). In both F9 vin
 
 
 
/
 
 
 
 and F9 vin
 
 
 
/
 
 
 
Y822F cells, detachment led to ERK1/2 activation sub-
stantially above that in WT F9 cells. In contrast, F9 vin
 
 
 
/
 
 
 
hinge-tail cells showed ERK1/2 activation inhibited to levels
seen in the wild-type cells. In F9 vin
 
 
 
/
 
 
 
 cells stably trans-
fected with vinculin, ERK1/2 activity after detachment was
the same as in WT F9 cells (Fig. 5 F).
ERK1/2 was recently shown to down-regulate apoptosis
by inhibiting activation of caspase-9 (Allan et al., 2003).
Caspase-9 is an initiator protease that activates caspase-3 and
other downstream caspases to trigger apoptosis, and it has
been found to be particularly important in anoikis (Gross-
Figure 3. Role of various regions of 
vinculin in the control of apoptosis 
induction. (A) Cell extracts from WT F9 
and F9 vin
 /  cells ( 229 clone) stably 
expressing each construct were analyzed 
by immunoblotting using anti–caspase-3 
Ab 10 h after serum withdrawal. (B) 
DEVD-AMC cleavage was compared for 
WT F9 cells versus F9 vin
 /  cells stably 
expressing each construct 10 h after 
serum withdrawal. (C) Immunoblotting 
analysis of cell extracts from WT F9 and 
F9 vin
 /  cells stably expressing each 
construct 3 h after disruption of cell–
matrix interaction using anti–caspase-3 
Ab. (D) DEVD-AMC cleavage was 
compared for WT F9 cells versus F9 
vin
 /  cells stably expressing vinY822F 
mutant and the hinge-tail fragment 3 h 
after disruption of cell–matrix interaction. 
(B and D) Results shown are means   
SEM from at least three independent 
experiments, in arbitrary fluorescence 
intensity units. 
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mann et al., 2001). Therefore, we examined caspase-9 acti-
vation after cellular detachment. WT F9, rescue, and F9
vin
 
 
 
/
 
  
 
hinge-tail cells showed cleaved caspase-9 30 min after
cellular detachment (Fig. 5 G). In contrast, no cleaved cas-
pase-9 was observed in F9 vin
 
 
 
/
 
 
 
 and F9 vin
 
 
 
/
 
 
 
Y822F cells
(Fig. 5 G). Together, these data indicate that vinculin affects
apoptosis by regulating ERK1/2 activity through a mecha-
nism requiring the hinge-tail region.
PI-3K is another signaling molecule that localizes into fo-
cal adhesions and affects both motility and apoptosis (Wat-
ton and Downward, 1999; Sasaki et al., 2000). We assessed
whether or not vinculin affects apoptosis by regulating this
pathway. As seen in Fig. 5 H, treatment of F9 vin
 
 
 
/
 
 
 
 and F9
vin
 
 
 
/
 
 
 
Y822F cells with Wortmannin (50 
 
 
 
M), an inhibitor
of PI-3K activity, was unable to restore apoptosis to wild-
type levels. These results indicated that the survival pathway
affected in vin
 
 
 
/
 
 
 
 and vin
 
 
 
/
 
 
 
Y822F cells does not involve
PI-3K. The WT F9 cells did exhibit more cell death upon
inhibition of PI-3K, perhaps because they lack the enhanced
survival mechanism produced by altering vinculin.
 
Vinculin regulates ERK1/2 activity through modulation 
of paxillin–FAK interaction
 
We found that vinculin regulates apoptosis via the ERK1/2
pathway, and that this regulation requires the vinculin
hinge-tail region. The hinge-tail fragment is targeted to focal
adhesions, where it colocalizes with the adaptor protein pax-
illin (Xu et al., 1998b). Furthermore, the vinculin tail do-
main and the FAT region of FAK bind to overlapping
paxillin LD motifs (Turner et al., 1999; Turner, 2000;
Tumbarello et al., 2002). FAK is an adaptor protein whose
kinase activity is involved in the activation of ERK1/2, cell
survival, and motility (Schwartz, 2001; Hauck et al., 2002).
Therefore, we tested if the paxillin–FAK interaction is af-
fected by vinculin.
To gauge the level of paxillin–FAK binding in different
cell lysates, either paxillin or FAK were immunoprecipitated,
and Western blotting was used to probe for the presence of
the binding partner (Fig. 6, A and B). Paxillin–FAK interac-
tion was enhanced relative to WT F9 cells in vin
 
 
 
/
 
 
 
 and
vinY822F cells. In contrast, paxillin–FAK binding is at wild-
type levels in F9 vin
 
 
 
/
 
  
 
hinge-tail and rescue cells (Fig. 6, A
and B).
FAK interaction with paxillin, coupled with phosphoryla-
tion of both proteins, creates docking sites for signaling mol-
ecules involved in cell motility and survival (Turner, 2000;
Schwartz, 2001; Hauck et al., 2002). Phosphorylation of
FAK at tyrosine 397 (Y397) is critical for the induction of
downstream effects (Hauck et al., 2000, 2002; Schwartz,
2001), including phosphorylation of paxillin at Tyrosine
118 (Y118; Turner, 2000). We assessed whether or not the
enhanced paxillin–FAK interaction in F9 vin
 
 /  and F9
vin
 / Y822F cells correlated with increased phosphorylation
of FAK-Y 397 and paxillin-Y118. The data in Fig. 7 (A and
B) show that these cells do in fact have constitutively in-
creased FAK-Y397 and paxillin-Y118 phosphorylation. Af-
ter cellular detachment, phosphorylation at these sites
rapidly decreased (Fig. 7, A and B). In contrast, phosphory-
lation at both sites is at wild-type levels in F9 vin
 /  hinge-
tail cells as well as rescue cells (Fig. 7, A and B), both consti-
tutively and during anoikis.
Finally, we examined cells overexpressing paxillin mutated
at the residues phosphorylated upon FAK interaction (paxil-
lin Y31FY118F; Turner, 2000). This mutant disrupts im-
portant signaling events activated by the paxillin–FAK in-
teraction (Petit et al., 2000). Overexpression of paxillin
Y31FY118F restored anoikis in F9 vin
 /  and F9 vin
 / 
Y822F cells to wild-type levels (Fig. 8 A). Importantly, this
mutant also inhibited the enhanced ERK1/2 activity during
cellular detachment (Fig. 8 B). Together, these data indicate
Figure 4. Role of various regions of vinculin in the control of 
apoptosis induction in a different F9 vin
 /  clone ( 227). (A) Cell 
extracts from WT F9 and F9 vin
 /  cells ( 227 clone) stably expressing 
each construct were analyzed by immunoblotting using anti–caspase-3 
Ab 10 h after serum withdrawal. (B) Immunoblotting analysis of cell 
extracts from WT F9 and F9 vin
 /  cells stably expressing each 
construct 3 h after disruption of cell–matrix interaction using anti–
caspase-3 Ab. The results shown in A and B are representative 
examples from two independent experiments. (C) Expression of 
full-length vinculin, head,   talin bs, and vinY822F in  227 clones. 
(D) Expression of the Flag M2–tagged hinge-tail fragment in  229 
and  227 clones.376 The Journal of Cell Biology | Volume 165, Number 3, 2004
that vinculin controls cell survival via ERK by regulating
paxillin–FAK interaction.
Vinculin regulates motility via paxillin and
ERK1/2 activation
A previously published paper showed that the enhanced mo-
tility of F9 vin
 /  cells was inhibited by expression of the
vinculin hinge-tail fragment (Xu et al., 1998b). Because cel-
lular motility and survival can be regulated by the same sig-
naling pathways (Cho and Klemke, 2000), we assessed
whether or not vinculin controls motility as well as apoptosis
via ERK1/2 activation, and whether or not this is also de-
pendent on paxillin–FAK interaction. In a Boyden chamber
assay, WT F9 cells migrated significantly less than either F9
vin
 /  cells or F9 vin
 / Y822F cells. Incubation with the
MEK inhibitor PD 98059 led to a 50–55% inhibition of F9
vin
 /  migration rates and decreased the enhanced migra-
tion of F9 vin
 / Y822F cells to wild-type levels (Fig. 9 A).
The drug had little effect on the migration of WT F9 cells.
We had shown that expression of the paxillin Y31FY118F
mutant led to restoration of anoikis in F9 vin
 /  and F9
vin
 / Y882F cells. As seen in Fig. 9 B, overexpression of this
mutant led to a remarkable inhibition of enhanced cell mi-
gration in F9 vin
 /  and F9 vin
 / Y822F cells. These find-
ings indicate that vinculin regulates both motility and sur-
vival through paxillin and ERK1/2 activation.
Discussion
Vinculin has a well characterized function as a cytoskeletal
protein within adhesion complexes (Rudiger, 1998), but
much of its role in signaling remains obscure. Tissue homeo-
Figure 5. Vinculin controls apoptosis 
induction by regulating ERK activity. 
(A) WT F9, F9 vin
 / , and F9 vin
 / Y822F 
cells were transfected with antisense 
ERK 1/2 and scrambled control oligonu-
cleotides. DEVD-AMC cleavage was 
assayed 3 h after disruption of cell–
matrix interaction. (B) Detergent lysates 
from these cells were analyzed by 
immunoblotting using anti-ERK1/2 and 
MEK Abs. The result shown are represen-
tative of three independent experiments. 
(C) WT F9, F9 vin
 / , and F9 vin
 / Y822F 
cells were left untreated or treated with 
10  M PD 98059 3 h before they were 
detached from gelatin-coated plates and 
during anoikis. DEVD-AMC cleavage 
was measured 3 h after disruption of 
cell–matrix interaction. Means   SEM 
were calculated from at least three 
independent experiments. (D) WT F9, 
F9 vin
 / , and F9 vin
 / Y822F cells were 
left untreated or treated with 10  M PD 
98059 3 h before detachment from 
gelatin-coated plates and during anoikis. 
Detergent lysates of cells were analyzed 
by immunoblotting using anti-ERK1/2 
and anti-phosphoERK1/2 Abs 30 min 
after disruption of cell–matrix interaction. 
The result shown is a representative 
example from two independent experi-
ments. (E) A representative immunoblot 
of three showing phosphorylated ERK1/2 
from WT F9, F9 vin
 / , F9 vin
 / Y822F, 
and F9 vin
 /  hinge-tail cells after 
disruption of cell–matrix interactions. 
(F) A representative immunoblot of two 
showing phosphorylated ERK1/2 from 
WT F9, F9 vin
 / , and rescue cells. (G) 
Detergent lysates from WT F9, F9 vin
 / , 
rescue, F9 vin
 / Y822F, and F9 vin
 /  
hinge-tail cells were analyzed by immu-
noblotting using anti–caspase-9 Ab 30 min 
after disruption of cell–matrix interaction. 
The result is a representative example 
from two independent experiments. 
(H) WT F9, F9 vin
 / , and F9 vin
 / Y822F cells were left untreated or treated with 50 nM Wortmannin 1 h before they were detached from 
gelatin-coated plates and during anoikis. DEVD-AMC cleaving caspases activity was assayed 3 h after disruption of cell–matrix interactions. 
Means   SEM were calculated from at least three independent experiments. A, C, and H show arbitrary fluorescence intensity units.Vinculin, paxillin, and FAK regulate apoptosis and motility | Subauste et al. 377
stasis is determined by the tightly regulated recruitment of
signaling molecules (Huang and Ingber, 2000), such as FAK
(Hauck et al., 2002) and paxillin (Turner, 2000; Schwartz,
2001), to specific subcellular locations. Our results demon-
strate that vinculin controls both motility and survival by af-
fecting ERK1/2 activity through modulation of paxillin–
FAK interaction.
Vinculin null cells showed reduced susceptibility to apop-
tosis induced by either serum withdrawal, perturbation of
cell attachment (anoikis), or camptothecin. Effects in these
very different apoptosis induction pathways suggest that vin-
culin participates in one or more conserved and fundamen-
tal pathways. Reintroduction of vinculin was able to rescue
normal apoptosis, proving that these results were not simply
due to a compensatory mutation during the production of
the vinculin null cells. By examining apoptosis after intro-
duction of various vinculin mutants into vin
 /  cells, we
pinpointed the vinculin hinge-tail fragment (811–1066 aa)
as essential for apoptosis regulation.
These experiments also suggested that vinculin’s effect on
apoptosis was dependent on its localization in focal adhe-
sions. The hinge-tail fragment, which did restore apoptosis,
is localized in focal adhesions and colocalizes with paxillin
(Xu et al., 1998b). In contrast,   Talin bs mutant (243–
1066 aa) is unable to localize in focal adhesions (Goldmann
et al., 1998) and was unable to restore apoptosis in vin
 / 
cells. According to earlier works, the   talin bs (243–1066
aa) mutant would be expected to incorporate in focal adhe-
sions through its tail domain; these works indicated that vin-
culin could target focal adhesions through both a talin bind-
ing site and another binding site in the tail (Bendori et al.,
1989). These conclusions were based on the fact that a vin-
culin construct lacking 167–207 aa, thought to be vinculin’s
only talin binding site, was still able to incorporate into focal
adhesions (Bendori et al., 1989). Later studies showed that
vinculin’s talin binding site actually extends from 1 to 253
aa (Gilmore et al., 1992). Thus, the vinculin construct lack-
ing 167–207 aa still had residues involved in vinculin’s in-
teraction with talin, which could mediate localization into
focal adhesions. In fact, a vinculin fragment consisting of
1–130 aa shows good talin binding (Bass et al., 2002), and a
recent paper (Izard et al., 2004) has shown that talin’s inter-
action with vinculin is critical for opening vinculin into its
active conformation. Talin’s interaction with vinculin causes
vinculin’s tail to dissociate from its head (Izard et al., 2004).
Thus, the   talin bs mutant could not incorporate into the
focal adhesion (Goldmann et al., 1998), as there was no talin
binding to disrupt the high affinity interaction of its tail and
residual head domain. The much smaller hinge-tail fragment
is capable of incorporating into focal adhesions because it is
completely devoid of vinculin’s inhibitory head domain (Xu
et al., 1998b).
Apoptosis resistance in vin
 /  and vinY822F cells was
ERK dependent. This conclusion is based on the fact that
apoptosis of both F9 vin
 /  and F9 vin
 / Y822F cells could
be restored to wild-type levels using ERK antisense oligonu-
cleotides or the MEK inhibitor PD98059. Moreover, recov-
ery of apoptosis in F9 vin
 /  hinge-tail cells was associated
with a reduction of ERK1/2 activity to wild-type levels, and
apoptosis-resistant F9 vin
 /  and F9 vin
 / Y822F cells
showed increased ERK1/2 activation after cellular detach-
ment. Increased ERK1/2 phosphorylation after cellular de-
Figure 6. F9 vin
 / and F9 vin
 / Y822F cells have an increased 
paxillin–FAK interaction. (A) Cell extracts from WT F9, F9 vin
 / , 
rescue, F9 vin
 / Y822F, and F9 vin
 /  hinge-tail cells were immuno-
precipitated with a mouse antipaxillin Ab, followed by immunoblotting 
with Ab against FAK. (B) Cell extracts from WT F9, F9 vin
 / , rescue, 
F9 vin
 / Y822F, and F9 vin
 /  hinge-tail cells were immunoprecipi-
tated with a mouse anti-FAK Ab, followed by immunoblotting with 
Ab against paxillin. The results shown are representative examples 
from three independent experiments.
Figure 7. F9 vin 
 /  and F9 vin
 / Y822F cells have increased 
FAK-Y397 and paxillin-Y118 phosphorylation. (A) A representative 
immunoblot showing FAK phosphorylated at Y397 in WT F9, F9 
vin
 / , rescue, F9 vin
 / Y822F, and F9 vin
 /  hinge-tail cells after 
disruption of cell–matrix interactions. (B) An immunoblot showing 
paxillin phosphorylated at Y118 in WT F9, F9 vin
 / , rescue, F9 
vin
 / Y822F, and F9 vin
 /  hinge-tail cells after disruption of cell–
matrix interactions. The results shown are representative of three 
independent experiments.378 The Journal of Cell Biology | Volume 165, Number 3, 2004
tachment has been shown before in apoptosis-resistant lung
adenocarcinoma cells (Wei et al., 2001). However, in con-
trast to our work, apoptosis resistance in these tumoral cells
was ERK1/2-independent (Wei et al., 2001). Differences in
the experimental design may account for this discrepancy.
Specifically, in the present work, we inhibited ERK activity
with PD98059 and ERK antisense oligonucleotides before
cellular detachment, whereas in the previous work (Wei et
al., 2001), ERK1/2 activity was inhibited with PD98059 af-
ter cellular detachment. This might be an important issue
because basal activity levels might determine if a cell survives
or dies upon apoptosis induction (Howe et al., 2002). How-
ever, consistent with our work, there was no difference
in the constitutive ERK1/2 phosphorylation levels among
apoptosis-resistant and apoptosis-sensitive cells (Wei et al.,
2001). It is possible that only a small fraction of the total
cellular ERK is involved in this regulation. ERK1/2 is
known to be compartmentalized in various subcellular loca-
tions (Reffas and Schlegel, 2000; Pouyssegur et al., 2002;
Smith et al., 2004).
Combining our own data with previous studies suggested
that vinculin regulates motility and survival by affecting pax-
illin–FAK interaction. Expression of a vinculin hinge-tail
fragment in F9 vin
 /  cells reduced FAK-Y397 phosphory-
lation, cell motility (Xu et al., 1998b), and ERK1/2-depen-
dent cell survival. These effects are very similar to those pro-
duced by transfection with FAK fragments containing the
sequence of the FAT region, which also inhibits FAK-Y397
phosphorylation and downstream effects, including cell mo-
tility and survival (Richardson and Parsons, 1996; Hauck et
al., 2000). Interestingly, the vinculin tail domain and the
FAT region bind to overlapping paxillin LD motifs (Turner
et al., 1999; Turner, 2000; Tumbarello et al., 2002). The
FAT region contains two distinct paxillin binding subdo-
Figure 8. Expression of paxillin Y31F and Y118F in F9 vin
 /  and 
F9 vin
 / Y822F cells restores apoptosis and reduces ERK activity to 
wild-type levels. (A) WT F9, F9 vin
 / , and F9 vin
 / Y822F cells 
were transfected with paxillin Y31FY118F-myc, wild-type paxillin-
myc, or control mRFP-myc plasmids. DEVD-AMC cleavage was 
assayed 3 h after disruption of cell–matrix interaction. Means   SEM 
were calculated from four independent experiments. (B) WT F9, F9 
vin
 / , and F9 vin
 / Y822F were transfected with paxillin Y31FY118F-
myc, wild-type paxillin-myc, or control mRFP-myc plasmids. 
Detergent lysates were analyzed by immunoblotting using ERK1/2 
and anti-phosphoERK1/2 Abs 30 min after disruption of cell–matrix 
interaction. (C) Expression levels of control mRFP-myc, wild-type 
paxillin-myc, and paxillin Y31FY118F-myc proteins in WT F9, F9 
vin
 / , and F9 vin
 / Y822F cells. DEVD-AMC cleavage is shown in 
arbitrary fluorescence intensity units. The results shown in B and C 
are representative of three independent experiments.
Figure 9. Enhanced motility in F9 vin
 /  and F9 vin
 / Y822F cells is 
restored to wild-type levels upon inhibition of MEK and expression 
of paxillin Y31FY118F. (A) WT F9, F9 vin
 / , and F9 vin
 / Y822F 
cells were left untreated or treated with 10  M PD 98059 3 h before 
they were detached from gelatin-coated plates for cell migration 
assays. Cells were allowed to migrate for 8 h using Boyden chambers 
coated with collagen. Mean number of cells per field   SEM was 
calculated from at least three independent experiments. (B) WT F9, 
F9 vin
 / , and F9 vin
 / Y822F cells were transfected with paxillin 
Y31FY118F and wild-type paxillin. Cell migration was quantified as 
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mains (Turner et al., 1999; Tumbarello et al., 2002), which
bind to paxillin LD2 and LD4 motifs (Hayashi et al., 2002).
The tail domain of vinculin is capable of binding paxillin
LD1, LD2, or LD4 motifs (Turner et al., 1999; Tumbarello
et al., 2002). Vinculin oligomers (Rudiger, 1998) could
bind simultaneously to paxillin LD2 and LD4 motifs from
the same paxillin molecules, thus interfering with FAK bind-
ing. We showed that the highly motile and apoptosis-resis-
tant F9 vin
 /  cells did in fact exhibit enhanced paxillin–
FAK interaction, and this was inhibited to wild-type levels
upon expression of the vinculin hinge-tail region.
Paxillin–FAK interaction leads to paxillin phosphoryla-
tion at Y31 and Y118 (Turner, 2000). We addressed
whether or not paxillin phosphorylation at these sites is me-
diating the increased motility and survival in F9 vin
 /  and
F9 vin
 / Y822F cells. Expression of a paxillin Y31FY118F
mutant in these cells led to a substantial reduction in motil-
ity and survival mediated by ERK1/2. The link between
paxillin–FAK binding and ERK activation may be through
Crk, an important adaptor molecule involved in ERK1/2 ac-
tivation (York et al., 1998). A previous paper demonstrated
that paxillin Y31 and Y118 phosphorylation creates docking
sites for Crk (Petit et al., 2000).
We also found that vinculin with a Y822F point mutation
was unable to restore normal apoptosis induction. These
profound effects from a point mutation strongly suggest that
enhanced survival is not due to nonspecific cytoskeletal al-
terations, but rather from specific effects in survival signaling
pathways (Judson et al., 1999; Rodina et al., 1999; Sattler et
al., 2000; Turner, 2000; Hauck et al., 2002). Previous
works indicate that the observed effects were not due simply
to an inability of the mutant to localize in focal adhesions
(Goldmann et al., 1998). Y822 is very close to the flexible
hinge region of vinculin, so the mutation could affect the
equilibrium between the open and closed form of the pro-
tein. When vinculin is in its open, active conformation it
localizes into focal adhesions (Rudiger, 1998). Upon bind-
ing to phosphatidylinositol(4,5)-biphosphate (Steimle et al.,
1999) at the cell membrane, vinculin unfolds, exposing its
talin binding sites (Johnson and Craig, 1994). The talin
binding sites are also critical for vinculin’s focal adhesion lo-
calization in cells (Goldmann et al., 1998). In contrast, pax-
illin interactions are not sufficient to cause vinculin localiza-
tion to focal adhesions in vivo (Goldmann et al., 1998),
despite the fact that paxillin–vinculin interaction in vitro oc-
curs for both open and closed conformations (Gilmore and
Burridge, 1996). The Y822F mutation could decrease the
stability of vinculin’s open conformation, affecting an early
stage of this complex process, before paxillin interaction.
Vinculin can be tyrosine phosphorylated (Sefton et al.,
1981), and Y822 is a putative site for phosphorylation
(Jockusch and Rudiger, 1996), but a physiological role for
Y822 phosphorylation has not been demonstrated (Jockusch
and Rudiger, 1996). Phosphorylation may be important for
maintaining the open conformation, as for the cytoskeletal
protein ezrin (Berryman et al., 1995). Thus, vinculin Y822F
could be more prone than wild-type vinculin to adopt a
closed conformation after its incorporation into focal adhe-
sions. Elucidating the precise mechanism through which
vinculin Y822F affects interactions with paxillin may be a
valuable route to further understanding of cell motility and
survival.
Understanding how cell motility and survival are regu-
lated is an important fundamental goal in cell biology. Mo-
tility and survival are controlled by multimolecular signaling
complexes created upon dynamic interaction between paxil-
lin and FAK. Our results identify vinculin as a key molecule
regulating these cellular processes and provides evidence
of an important signaling mechanism tying vinculin to
carcinogenesis.
Materials and methods
Cell culture
The following cell lines were used: WT F9 mouse embryonal carcinoma
cells and vinculin-null F9 cells (F9 vin
 /  clones  229 and  227; Coll et
al., 1995); F9 vin
 /  cells stably transfected with plasmid vectors express-
ing full-length vinculin (F9 vin
 /  rescue); a fragment containing the se-
quences of the head portion of vinculin (F9 vin
 /  head, 1 to 821 aa); a vin-
culin fragment 243–1066 in which the talin binding sites were deleted (F9
vin
 /    talin bs); a full-length vinculin containing a Y822F point mutation
(F9 vin
 / Y822F); and cells expressing a vinculin hinge-tail fragment (F9
vin
 /  hinge-tail, amino acid residues 811 to 1066), which was Flag M2-
tagged (Xu et al., 1998b). These cells were cultured as described previ-
ously (Coll et al., 1995; Xu et al., 1998b).
Anoikis assay
Anoikis assays were performed according to a published protocol (Folk-
man and Moscona, 1978). In brief, 6-well plates (Costar) were coated with
polyHEMA to create a nonadhesive surface. The wells were allowed to dry
for 48 h and washed with PBS (GIBCO BRL) before experiments. Cells
were added in each well at a concentration of 5   10
5 cells ml
 1, and the
extent of apoptotic cell death was determined 3 h later.
Live cell microscopy for apoptosis
Immediately before the experiment, the medium was changed to PBS sup-
plemented with 10% FBS. Gelatin-coated coverslips with adherent F9, F9
vin
 / , and F9 vin 
 /  rescue cells were mounted in a sealed Dvorak cham-
ber (Nicholson Instruments) held in a temperature-controlled stage (20/20
Technologies). Microscopy was performed using a microscope (model Ax-
iovert 100 TV; Carl Zeiss MicroImaging, Inc.) modified with automated
stage and filter wheels (LEP Ltd.) and a 40  NA 1.3 objective with differ-
ential interference contrast optics (Carl Zeiss MicroImaging, Inc.). Control
of microscope automation and image analysis were performed using Inovi-
sion ISEE software. The extent of apoptotic cell death was assessed during
the first 6 h after addition of 2  M camptothecin (Sigma-Aldrich). As de-
scribed previously (Subauste et al., 2000), individual cells were logged in
using the automated microscope and scored for changes in morphology
over time. Previously reported studies confirmed that the morphological
features assayed (contraction and blebbing leading to cell fragmentation)
were indicative of apoptosis (Subauste et al., 2000).
Caspase activity assay
The synthetic tetrapeptide fluorogenic substrate DEVD-AMC from Enzyme
Systems Products was used as described previously (Subauste et al., 2000).
Preparation of protein extracts, immunoblotting, and 
immunoprecipitation
For immunoblotting analyses, cells were lysed in a buffer containing 20
mM Tris-HCl, pH 8, 100 mM NaCl, 10% glycerol, 1% Triton X-100, 50
mM NaF, 1 mM sodium vanadate, 1 mM benzamidine, 5  g ml
 1 leupep-
tin, and 1 mM PMSF. The cell lysates were clarified at 10,000 g for 10 min
at 4 C. Samples were separated on SDS–polyacrylamide gels (Bio-Rad Lab-
oratories). Proteins were transferred to Immobilon-P transfer membranes
(Millipore) and blocked and probed with the following Abs: rabbit anti-
ERK1/2 Ab, rabbit anti-phospho ERK1/2 (Thr202/Tyr204) Ab, rabbit anti-
MEK Ab, rabbit antiphospho paxillin (Tyr118) Ab, and rabbit anti–Caspase-3
Ab from Cell Signaling Technology; rabbit anti-FAK Ab from Santa Cruz
Biotechnology, Inc.; mouse monoclonal antipaxillin Ab; mouse monoclo-
nal antiphospho FAK (Tyr 397) Ab from Becton Dickinson; rabbit anti–Cas-
pase-9 Ab from BD Biosciences; and mouse monoclonal antivinculin Ab,
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Ab from Sigma-Aldrich. Bound Ab was detected by incubation with sec-
ondary Abs conjugated with HRP (rabbit and mouse HRP–derived Ab were
obtained from Cell Signaling) and visualized by ECL (Pierce Chemical
Co.). Equal loading in each lane was verified by assessing their ERK1/2
concentration.
Immunoprecipitation studies that assessed the interaction of FAK with
paxillin were performed according to procedure described previously
(Tachibana et al., 1995) with some minor modifications using the mouse
monoclonal antipaxillin Ab as well as the rabbit anti-FAK Ab (the concen-
tration used for both Abs was of 1/500).
Cell migration assays
Modified Boyden chambers (8  m pore size; Transwell Costar Corpora-
tion) were used in cell migration assays. The filter inserts were coated with
10  g ml
 1 collagen type I (Upstate Biotechnology) for 2 h at 37 C, rinsed
with PBS, and the inserts were placed into the lower chamber containing
0.5 ml of  -MEM media containing 10% FBS (GIBCO BRL). 2   10
5 cells
that were previously serum starved (1% FBS) for 10 h were added to the
top of each migration chamber and allowed to migrate to the underside of
the top chamber for 8 h. Nonmigratory cells on the upper membrane sur-
face were removed with a cotton swab, and the migratory cells attached to
the bottom surface of the membrane were fixed with methanol and stained
with 0.1% crystal violet in 0.1 M borate (Sigma-Aldrich), pH 9, and 2%
ethanol for 20 min at RT. The number of migratory cells per membrane
was counted with an inverted microscope (Nikon) using a 10  objective.
Each determination represents the average of two individual wells. Back-
ground migration was assessed on BSA (1%)-coated membranes and sub-
tracted from all data.
Inhibition of p42 and p44 MAPK (ERK1 and ERK2) with Erk 
antisense oligonucleotides
Depletion of MAPK (ERK1 and 2) from F9 embryonal carcinoma cells was
performed using phosphorothioate-protected oligonucleotides according
to the procedure of Sale et al. (1995) with some modifications. Erk anti-
sense (5 -GCC GCC GCC GCC GCC AT-3 ) and control oligonucleotides
(5 -CGC GCG CTC GCG CAC CC-3 ) were HPLC purified (Operon Bio-
technology). Cells were grown to 30% confluency in 6-well tissue culture
plates. Before transfection, lipofectin (GIBCO BRL) was diluted into 400  l
 -MEM at a concentration of 30  g/ml for 40 min at RT. The diluted lipo-
fectin was mixed with 400  l  -MEM containing 6.0  M ERK antisense or
control phosphorothioate oligonucleotides for 15 min at RT. This mixture
was added to the cells. The final concentrations of lipofectin and oligonu-
cleotides were 15  g/ml and 3  M, respectively. Cells were incubated for
8 h at 37 C in the presence of 5% CO2. They were rinsed, incubated for
another 40 h in fresh culture medium containing oligonucleotides, and
tested as described in Anoikis assays. An aliquot of the aforementioned
cells was analyzed in parallel for changes in ERK protein levels using ERK-
specific Abs and immunoblotting as described in Preparation of protein ex-
tracts, immunoblotting, and immunoprecipitation. As a control for nonspe-
cific depletion of proteins, MEK concentration of each sample was as-
sessed by immunoblotting.
Plasmids and transfection
pcDNA3 wild-type and Y31FY118F paxillin constructs were previously
described (Petit et al., 2000). To myc tag these constructs at their NH2 ter-
minus, they were excised with BamHI and EcoRI enzymes and subcloned
in a pTriExx4 His-myc vector. A monomeric red fluorescent protein
(mRFP) subcloned in the same vector was used as a control. Transient
transfections were done using lipofectamine and Plus Reagent (GIBCO
BRL) following the manufacturer’s instructions. In brief, F9 cell lines were
transfected with 8  l lipofectamine, 16  l of Plus Reagent, and 7  g of the
plasmids. Cells were used 48 h after transfection. The plasmids expressions
were confirmed with a mouse anti-myc Ab (Sigma-Aldrich).
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